CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

pembrolizumab

Last Updated: December 23, 2020
Result type: Reports
Project Number: PC0235-000
Product Line: Reimbursement Review

Generic Name: pembrolizumab

Brand Name: Keytruda

Manufacturer: Merck Canada Inc.

Therapeutic Area: Colorectal cancer

Indications: ​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

Manufacturer Requested Reimbursement Criteria1: For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: Yes

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 02, 2020
Call for patient/clinician input closedDecember 24, 2020
Clarification:

- Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network

Submission receivedNovember 30, 2020
Submission acceptedDecember 14, 2020
Review initiatedDecember 15, 2020
Draft CADTH review report(s) provided to sponsor for commentMarch 08, 2021
Deadline for sponsors commentsMarch 17, 2021
CADTH responses on draft review report(s) provided to sponsorMay 03, 2021
Expert committee meeting (initial)May 13, 2021
Draft recommendation issued to sponsorMay 26, 2021
To
May 28, 2021
Draft recommendation posted for stakeholder feedback-